References
Nabhan C, Rosen ST (2014) Chronic lymphocytic leukemia: a clinical review. JAMA 312:2265–2276
Byrd JC, Furman RR, Coutre SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42
Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507–516
Byrd JC, Brown JR, O’Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213–223
Byrd JC, Furman RR, Coutre SE et al (2015) Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood [Internet] Available from: http://www.bloodjournal.org/content/early/2015/02/23/blood-2014-10-606038 [cited 2015 Mar 23]
Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 24:71–81
Al-Anazi KA, Al-Jasser AM, Alsaleh K (2014) Infections caused by mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol. doi:10.3389/fonc.2014.00231
Dubovsky JA, Beckwith KA, Natarajan G et al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539–2549
Conflict of interest
No conflict of interest is declared.
Author information
Authors and Affiliations
Corresponding author
Additional information
Song-Yau Wang and Thomas Ebert contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wang, SY., Ebert, T., Jaekel, N. et al. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Ann Hematol 94, 1419–1420 (2015). https://doi.org/10.1007/s00277-015-2385-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2385-0